Eptifibatide
As of the edition of 20 October 2026, Eptifibatide is a protein: marketed, first approved in 1998 (US); acts on ITGA2B; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Protein
- Brand name
- Integrilin
- First approved
- 18 May 1998 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Merck & Co.
- Withdrawn from market
- 1 January 2026 (in some regions)
- Registered trials
- 20, 5 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Infections; Blood and lymph; Inherited and neonatal; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Eptifibatide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ITGA2B | Integrin alpha-IIb | P08514 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 2 | 8 | 5 | 0 | 2 |
| Phase 3 | 7 | 4 | 1 | 1 |
| Phase 4 | 4 | 2 | 0 | 2 |
| All trials | 20 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Acquired holder | 2022 to now |